Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Justin Watts, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, reviews the current landscape of menin inhibitors in KMT2A-rearranged and NPM1-mutated acute myeloid leukemia (AML). Dr Watts highlights that responses to revumenib and ziftomenib in the AUGMENT-101 (NCT04065399) and KOMET-001 (NCT04067336) trials are limited by MEN1 resistance mutations. He also discusses the potential of the second-generation agents enzomenib, evaluated in the Horizen-1 trial (NCT04988555), and bleximenib, evaluated in the cAMeLot-1 trial (NCT04811560). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.